Effect of intravenous infusion of atriopeptin 3 on immediate renal allograft function  by Ratcliffe, P.J. et al.
Kidney International, Vol. 39 (1991), pp. 164—168
Effect of intravenous infusion of atriopeptin 3 on immediate
renal allograft function
P.J. RATCLIFFE, A.J. RICHARDSON, J.E. KIRBY, C. MOYSES, J.R. SHELTON, and P.J. MORRIS
Nuffield Department of Surgery Transplant Unit, Churchill Hospital, Oxford, and G.D. Searle and Company, London, England,
United Kingdom
Effect of intravenous infusion of atriopeptin 3 on immediate renal
allograft function. Thirty-eight recipients of nineteen pairs of cadaveric
kidneys were entered into a double-blind randomized study in which
one recipient received a 12-hour intravenous infusion of Atriopeptin III
(AP-3), a synthetic analogue of atrial natriuretic factor, commencing at
release of the vascular clamps, and the other received a placebo
infusion. In an initial dose ranging study, successive groups of six
kidneys (3 pairs) were randomized to receive each of 0.0125, 0.025, 0.05
gIkgImin AP-3 or placebo. Thereafter 20 kidneys (10 pairs) received
0.1 g/kg/min or placebo. There was no discernable effect of AP-3 on
allograft creatinine clearance or sodium excretion either when the
highest dose of AP-3 was considered alone or when all doses were
considered together. Averaged creatinine clearance over the period 0 to
24 hours after transplantation was 20.1 14.7 mI/mm in patients
receiving active treatment and 18.2 13.7 mI/mm in those receiving
placebo. Thus, despite the documentation of a protective effect of atrial
natriuretic factor in animal models of renal ischemia, it is unlikely that
intravenous infusion of AP-3 in this dose range will be of benefit in
improving immediate renal allograft graft function.
Atriopeptin III (SC 44900) (AP-3) is a synthetic 24 amino acid
peptide which belongs to a family of structurally related pep-
tides isolated from the mammalian atria [1].
The 24 amino acid peptide has similar biological effects to the
28 amino acid, human-cs atrial natriuretic peptide, which is the
main active molecular species in humans. Both are derived
from the C-terminus of a larger precursor. Renal effects of AP-3
include an increase in glomerular filtration rate, natriuresis and
diuresis [2, 3]. Furthermore, in a variety of animal models of
acute renal failure, intravenous or intrarenal infusion of AP-3 or
other atriopeptins can ameliorate the renal failure and a large
effect has been reported even when the infusion is given after
the ischemic insult [4—10]. These results led us to perform a
double-blind randomized study in human recipients of cadaver
renal allografts to determine the effect of AP-3 on post-ischemic
allograft function, when infused intravenously immediately
after transplantation.
Methods
Between February 1988 and January 1989, 19 pairs of cadav-
eric kidneys were entered into a double-blind randomized trial
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in which the recipients of each pair of kidneys were randomized
so that the recipient of the first kidney received a post-operative
infusion of AP-3 and the other recipient received a placebo
infusion or vice-versa. In each case the infusion was com-
menced in the operating theater when the vascular clamps were
released, and it ran for 12 hours. Active and placebo infusions
were delivered in 5% dextrose using an infusion pump operating
at a rate of 1 to 4 mllhr depending on dosage. All items used in
the delivery of peptide were tested for compatibility prior to the
study. Preparation of the infusions according to a predeter-
mined randomization schedule was performed by a coordinator
who was not involved in the clinical management of the
patients. Informed consent was obtained from all patients
pre-operatively, and pairs of kidneys were entered into the
randomization schedule only if both potential recipients had
consented. The trial protocol was approved by the Oxford
Hospitals Ethics Committee.
The study was performed in two phases. In an initial dose-
ranging study, successive groups of six kidneys (3 pairs) were
randomized to receive each of 0.0125, 0.025, 0.05 cg/kg/min or
placebo. Thereafter 20 kidneys (10 pairs) received 0.1 cgIkgI
mm or placebo. The doses were chosen on the basis of studies
establishing safety in this dose range in normal subjects [11].
All kidneys were retrieved by the Oxford Transplant Service
from beating heart donors. The kidneys were cooled in situ
using perfusion with hypertonic citrate solution and were pre-
served in ice slush. A standard surgical procedure was used for
transplantation [12]. The transplanted kidney was placed ex-
traperitoneally, with end to side anastomosis of the renal vein to
the external iliac vein and anastomosis of the Carrel patch of the
renal artery end to side to the external iliac artery. The ureteric
anastomosis was performed using a Leadbetter-Politano ure-
teroneocystostomy.
Central venous pressure monitoring was undertaken in all
patients, and during surgery patients were given intravenous
fluids to raise the central venous pressure to approximately 10
cm of water prior to release of the vascular clamps. Mannitol
12.5 g and frusemide 80 mg were administered intravenously at
this time. Post-operative colloid solutions were given to main-
tain the central venous pressure at 5 to 10 cm of water, and
crystalloid solutions were given at an hourly rate equal to the
hourly urine volume plus 50 to 100 ml. Inotropic, vasodilator or
diuretic agents were not used in the first 24 hours after release
of the vascular clamps.
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Table 1. Design factors and co-variates used in the analysis of
variance
Design factors
Treatment (active versus placebo)
Dose group
Donor within dose group
Treatment x dose group
Co-variates
Donor age
Cyclosporin use, 0—48 hr (present or absent)
Recipient age
Hemoglobin
Transplant sequence
Cold ischemia time
Arterial mean pressure 0—4 hr and 0—12 hr
Transplant sequence refers to the order in which kidneys were
implanted, the time difference between the first and second transplants
ranging from 3.0 to 12.4 hrs (mean 6.3 hrs).
Patients were immunosuppressed with a combination of
cyclosporine, azathioprine and prednisolone. In all except four
patients, cyclosporine was given orally pre-operatively (10
mg/kg), intravenously for four days following transplantation (4
mg/kg/day), and then orally again from day three post-opera-
tively (10 mg/kg/day) with the dose adjusted to obtain whole
blood trough levels in the range 400 to 800 ng/ml (polyclonal
assay, Sandoz). The other four patients, who received two pairs
of kidneys form pediatric donors, did not receive cyclosporine
until day five and instead received antithymocyte globulin
(Fresenius) for the first seven days after transplantation. Aza-
thioprine was given to all patients at a dose of 1.5 mg/kg/day
commencing immediately pre-operatively. Prednisolone was
given at a dose of 20 mg twice daily for the first 90 days. All
patients received intravenous cefuroxime 750 mg immediately
prior to surgery, and co-trimoxazole at a dose of 480 mg once
daily for six months after transplantation.
Biochemical analyses were performed on a multi-channel
analyzer. For calculation of the 0 to 12 hour, and 12 to 24 hour
creatinine clearances, the mean of plasma creatinine concentra-
tions in timed blood samples taken at 0 and 12 hours and 12 and
24 hours, respectively, was used. Plasma AP-3 levels were
measured by radioimmunoassay after storage of separated
plasma in liquid nitrogen.
Statistical analysis
Twelve outcome variables were examined to assess the
efficacy of AP-3: creatinine clearances (0 to 12 hr, 12 to 24 hr,
0 to 24 hr, day 3, day 7 and day 21), urine volume (0 to 12 hr, 0
to 24 hr), urine sodium excretion (0 to 12 hr and 12 to 24 hr) and
mean arterial blood pressure (0 to 12 hr and 12 to 24 hr).
Creatinine clearance was logarithmically transformed prior to
analysis to remove skewness in the distribution of the data and
to stabilize the variance. Each outcome variable was submitted
to an analysis of variance using PROC GLM of the SAS
software package. Design factors and co-variates used in the
analysis are listed in Table 1. Co-variates retained in the final
model were those significant at the 10% level using stepwise
elimination. The overall analysis included all dose levels and
assessed the possibility of a dose dependent effect of treatment
as well as an overall effect. The analysis was then repeated for
the high dose level (0.1 mg/kg/mm) alone.
Results
Of eight patients who required hemodialysis in the first seven
days after transplantation, five were in the group who received
the placebo and three had received AP-3. This difference is not
significant. All these patients subsequently recovered good
graft function. A further three patients required graft nephrec-
tomy between 7 and 21 days after transplantation. The indica-
tions were irreversible rejection in two cases (1 in the active
group and 1 in the placebo group) and thrombosis of the
transplant renal vein in one patient who had received placebo.
These three patients were omitted from the analysis of creati-
nine clearance at day 21.
Table 2 shows the results of the overall analysis for creatinine
clearance. When all patients were considered together, no
effect of treatment with AP-3 on creatinine clearance was
detected. Table 3 shows the mean values for creatinine clear-
ance at different doses of AP-3 together with the values in the
corresponding placebo treated groups. It can be seen that the
overall mean creatinine clearance was very similar between
groups receiving active and placebo treatment. When different
doses are considered, it is seen that 0 to 24 hour creatinine
clearances were higher in the actively treated patients at doses
of 0.025 and 0.05 igIkgImin than in the corresponding placebo
groups, whereas at doses of 0.0125 jig/kg/mm and 0.1 jig/kg/mm
they tended to be lower in the actively treated patients than in
the placebo group. This interaction between dose level and
treatment (active or placebo) was statistically significant (Table
2), but, it appears that the finding was due to unusually low
creatinine clearances in the small groups of patients receiving
the placebo for doses of 0.025 and 0.05 jig/kg/mm, suggesting
that these differences are not of clinical significance.
Among the co-variates examined in the analysis for graft
creatinine clearance, increasing donor age was associated with
lower creatinine clearances during the first 24 hours. On day
three this association was weaker and by day seven it had
disappeared. Figure 1 shows the association between donor age
and 0 to 24 hour creatinine clearance in patients receiving active
and placebo infusions. Transplant sequence was also associated
with creatinine clearances in the first 24 hours, the first trans-
plant tending to function better than the second. By day three,
this association was no longer significant.
Table 4 presents the overall analysis for the effect of treat-
ment on mean arterial blood pressure, urine volume and urinary
sodium excretion. Mean arterial blood pressure (0 to 12 hr) was
significantly lower on active treatment (106 12 mm Hg vs. 117
13 mm Hg). This difference was also apparent when the high
dose was considered alone (102 12mm Hg vs. 115 12 mm
Hg, P = 0.029). None of the co-variates was significantly
associated with blood pressure at this time. When all patients
were considered, there was no effect of treatment with AP-3 on
sodium excretion, but the mean urine volumes in the first 24
hours were slightly greater in patients receiving AP-3, the
difference just reaching statistical significance. As with creati-
nine clearances, there were differences between the small
groups receiving individual doses which appeared to arise
mainly from unusually low urinary volume and rates of sodium
excretion in the groups receiving placebo for dose levels of
0.025 and 0.05 jig/kg/mm.
In six pairs of recipients who received infusion of AP-3 at 0.1
166 Ratcl{Jfe et a!: Atriopeptin 3 and renal allograft function
Table 2. Overall analysis for the effects of treatment variables and co-variates on creatinine clearance
0—12 hr 12—24 hr 0—24 hr Day 3 Day 7 Day 21
Treatment variables
Treatment NS NS NS NS NS NS
Dose group NS NS NS NS NS NS
Treatment x dose group P < 0.001 P = 0.003 P <0.001 NS NS NS
Donor covariates
Donor age P = 0.075 P = 0.010 P 0.029 P = 0.062 NS NS
Cyclosporin use (0-48 hr) NS NS NS NS NS NS
Recipient covariates
Recipient age NS NS NS NS NS NS
Hemoglobin NS NS NS NS NS NS
Transplant sequence P = 0.003 P = 0.004 P 0.004 NS NS NS
Cold jschemia time NS NS NS NS NS NS
Treatment dependent covariates
Arterial mean pressure (0—4 hr) NS NS NS NS NS NS
Arterial mean pressure (0—12 hr) NS NS NS NS NS NS
Values of creatinine clearance were logarithmically transformed prior to this analysis; NS, not statistically significant, P > 0.1.
Table 3. Creatinine clearances (mi/mm) for all patients, active or placebo treatment at each dose level
0—12 hr 12—24 hr 0—24 hr Day 3 Day 7 Day 21
Active treatment
Dose ug/kg/min
0.0125 Mean 24.3 41,7 30.4 42.7 35.0 46.7
0.025 Mean 16.1 19.3 17.3 36.3 22.7 38.0
0.05 Mean 20.4 18.4 19.6 14.5 8.5 14.3
0.1 Mean 15.3 22.4 17.9 25.0 27.8 36.7
SD 12.4 21.2 15.2 24.6 18.8 11.4
Overall Mean 17.6 24.3 20.1 28.9 26.0 34.8
SD 12.3 20.6 14.7 24.1 16.9 14.7
Placebo treatment
Dose
0.0125 Mean 27.8 35.3 30.7 43.0 49.0 37.7
0.025 Mean 4.7 6.5 5.6 9.0 6.0 30.0
0.05 Mean 2.8 2.4 2.6 3.7 11.7 18.0
0.1 Mean 21.5 24.5 23.4 29.4 29.9 26.5
SD 10.7 13.3 9.8 19.1 14.1 18.3
Overall Mean 16.6 19.9 18.2 22.9 25.8 27.4
SD 12.8 16.5 13.6 19.7 20.8 19.2
For 0.0125, 0.025 and 0.05 jg/kg/min, N = 3. For 0.1 g/kmin, N = 10.
igIkg/min or placebo, plasma AP-3 levels were measured in the
final hour of the infusion. The mean level was 6383 pg/ml, and
the range was 1260 to 12500 pg/mI in those receiving active
infusions and 209 (range 99 to 327 pg/ml) in those receiving
placebo.
Discussion
Atriopeptin III had no important effect on immediate post-
ischemic allograft function as assessed by creatinine clearance
and urinary excretion of sodium and water. The similarity of
creatinine clearances in groups of transplanted patients receiv-
ing active or placebo infusions was surprising in view of the
marked amelioration of acute renal failure which has been
observed in animal models of acute renal failure using similar
doses of the peptides. These studies have demonstrated ame-
lioration of experimental renal failure in both rats [5—7] and dogs
[8, 9], and in models using both mechanical interruption of the
renal circulation [5—91 and intrarenal infusion of noradrenaline
[4] to produce renal ischemia. Amelioration of nephrotoxic
acute renal failure has been reported [13]. In contrast with many
protective maneuvers in experimental acute renal failure, infu-
sion of atriopeptins can be protective even when given after the
renal insult [5—91. In experimental studies infusions of atrio-
peptins have been effective when given either intravenously or
as intrarenal arterial infusions [61, and in doses ranging from
well below to well above the range used in this study. For
instance, Gianello et al found an infusion of 3.6 ng!kg/min to be
effective after renal artery clamping in the dog [9], whereas
Nakamoto et al found that a post-ischaemic infusion of 0.2
j.gIkgfmin was more effective than an infusion of 0.02 pgIkg/min
in the rat [7]. The dose range used in the current study was thus
intermediate in relation to these studies. No effect on allograft
function was seen either when the highest dose, 0.1 gIkg/min
was considered alone, or when all doses were combined.
Insufficient numbers of patients received the lower doses to
permit independent statistical analysis of the lower doses. At
0.0125 gIkg!min and 0.1 g/kg/min patients receiving placebo
infusion tended to have higher creatinine clearances, whereas
the reverse was true at 0.025 g/kg/min and 0.05 gIkgImin.
Inspection of the actual creatinine clearance values reveals that
groups receiving placebo infusion for 0.025 jgIkgImin and 0.05
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Table 4. Overall analysis for the effects of treatment variables and co-variates on arterial mean blood pressure, urine volume, and urinary
sodium excretion
Arterial mean pressure Urine volume Sodium excretion
0—12 hr 12—24 hr 0—12 hr 0—24 hr 0—12 hr 0—24 hr
Treatment variables
Treatment
Dose group
Treatment x dose group
P = 0.004
NS
NS
NS
NS
NS
P = 0.051
NS
P = 0.009
P = 0.039
NS
P = 0.012
NS
NS
P = 0.025
NS
NS
P = 0.029
NS, not statistically significant, P> 0.1. All co-variate NS for all outcome variables.
gIkg/min had unusually low creatinine clearances. There was
thus no evidence of a dose response for AP-3.
Additional evidence for the absence of an effect of AP-3 on
immediate allograft function is the similar incidence of primary
non-function in actively and placebo treated group, and a
similar spread of values for immediate creatinine clearance in
active and placebo treated patients (Fig. 1).
At day 21 creatinine clearance was higher in patients treated
with AP-3. Although this difference is not statistically signifi-
cant, it is possible that it represents a delayed effect of AP-3
which could be detected by a larger study. We consider this
possibility to be unlikely. First, in the animal studies which led
to the planning of this study the action of atriopeptins was, as
with other putative therapies for acute renal failure, most
evident on immediate post-ischemic function. Secondly, the
possibility of a difference in creatinine clearance only appears at
day 21 when other influences on graft function such as rejection
are more common. In the period 0 to seven days a similar
improvement in graft function took place in active and placebo
treated patients.
The plasma levels of AP-3 reached in the final hour of
infusion with AP-3 at 0.1 gIkgImin were considerably in excess
of the physiological range and somewhat higher than the levels
reached in normal individuals infused with AP-3 at the same
rate for five hours [11]. The variability in the plasma levels is
unexplained but might result from different clearance rates by
different renal allografts, since the kidney makes an important
contribution to plasma clearance [14]. The much lower levels
recorded in placebo treated patients most probably reflect cross
reactivity with retained human atrial natriuretic peptide metab-
olites. The cross reactivity of this assay with intact human a
ANP is 3.3%.
The synthetic peptide used is the rat amino acid sequence
which differs from the human in a single amino acid, position 8,
where the human methionine is substituted by isoleucine [3]. A
comparison of these peptides in dog has, however, revealed
identical activity. Comparison of the activity of AP-3 with the
28 amino acid aANP has, at least in one study, revealed greater
natriuretic activity with the 28 amino acid peptide [2]. How-
ever, a comparison of the two peptides in a study of post-
ischemic renal failure, in the rat revealed a similar amelioration
of the post-ischemic reduction in GFR but a higher natriuretic
activity with AP-3 [5]. Thus, animal studies have not revealed
differences in activity between peptides which could account
for the failure of AP-3 to improve immediate graft function in
this study.
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Fig. 1. The association between donor age0 (A, yrs) and mean creatinine clearance (C,
mI/mm) in the period 0 to 24 hrs is shown for
actively treated patients (•) and placebo
treated patients (0). In each group the
distribution of creatinine clearance is similar.
Overall there is an association between donor
age and 0 to 24 hr creatinine clearance. A
50 linear regression has been fitted to the data60 yielding the relationship C = —0.51 A + 35.5;
= 0.38, P < 0.05.
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The lower mean systemic pressure in patients receiving
active infusion was consistent with the reduction which has
been observed when the peptide has been infused in other
situations [1—3]. It could be argued that this effect might be
harmful to renal allograft perfusion either directly or by activa-
tion of vasoconstrictor homeostatic mechanisms, though
clearly, neural mechanisms [15] cannot operate in the newly
transplanted kidney. While we cannot exclude the possibility
that reduction in the systemic blood pressure might counterbal-
ance a beneficial effect of the peptide on allograft function, no
independent influence of systemic blood pressure on immediate
allograft function was observed, and in animal studies reduction
in blood pressure did not prevent amelioration of post-ischemic
renal failure [7].
We cannot, therefore, offer any certain explanation for the
difference between these results in humans and those obtained
in animal models. Three other points are worthy of note.
Firstly, not all animal models studied have been protected by
atriopeptin infusion. For instance, Shaw et al found that infu-
sion of atriopeptin protected a single ischemic kidney subjected
to 60 minutes renal artery occlusion. When the contralateral
kidney was left in situ, atriopeptin infusion protected against 45
minutes ischemia but not against 60 minutes ischemia [6].
Secondly, all except four of our patients received cyclosporin
A. It is, however, unlikely that this obscured an effect of AP-3,
since atriopeptins have, in animal studies, been shown to
ameliorate cyclosporine nephrotoxicity [16], and in any case
actively treated and placebo groups of patients received the
same dose of cyclosporin A. Thirdly, in most models of
experimental ischemia, blood cells remain within the renal
circulation throughout the period of ischemia, and post-is-
chemic vascular congestion may occur and contribute impor-
tantly to renal damage [17]. Ischemia in the cadaver renal
transplant is different since it is mainly cold ischemia, blood
cells are removed at the start of cold ischemia by perfusion.
Quite clearly, the pathophysiological mechanisms, which oper-
ate to produce the decrement in immediate creatinine clearance
observed in all of our patients, may differ importantly from
those which led to post-ischemic acute renal failure in animal
models.
One previous uncontrolled study has described the effect of
h-ANP infusions in six oligoanuric transplant recipients. In only
two did a diuresis commence during the h-ANP infusion [18].
However, in a preliminary report of a study in canine autografts
subject to 24 hours of cold ischemia, a beneficial effect of
post-ischemic infusion of h-ANP has been claimed [10].
In summary, despite considerable evidence from animal
studies showing amelioration of post-ischemic renal failure, no
effect on post-ischemic renal allograft function was observed in
humans suggesting that intravenous infusion of AP-3 at the
dosage used in this study is unlikely to be of benefit in this
clinical situation.
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